drugset / Trial / NCT05283434

Arnica and the Management of Pain in Acute Musculoskeletal Extremity Injuries

NCT05283434

Phase 2/3 Unknown 324 enrolled Children's Hospitals and Clinics of Minnesota
RandomizedParallel-groupTriple-blindTreatment

Summary

In the Emergency Department, there is no standard of care for pain medication distribution for children with an acute musculoskeletal injury when there is no fracture present. Currently, ibuprofen is a favorable choice for the treatment, but studies have shown concern for delayed healing activity associated with NSAIDs like Ibuprofen. Homeopathic Arnica Montana is a well-established complimentary medicine and may provide a good alternative for managing acute pain from musculoskeletal injuries, especially in children, given the palatability and rarity of side effects. This study aims to compare usual care vs. usual care plus Arnica 1M\* (oral) or the placebo for management of pain in acute musculoskeletal extremity injuries without fracture by utilizing a double-blind clinical trial design. The primary outcome is to determine if subjects use less ibuprofen when given Arnica 1M.

Timeline

Start
2021-07-15
Primary completion
2023-06-30
Completion
2023-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Arnica Traditional medicine (herbal / TCM) 2 unknown Oral

Indications

No indication recorded.